{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:17:22Z","timestamp":1775477842150,"version":"3.50.1"},"reference-count":168,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jhepr.2026.101748","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T16:32:03Z","timestamp":1769790723000},"page":"101748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation"],"prefix":"10.1016","volume":"8","author":[{"given":"Alexandra D.","family":"Frolkis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-0218","authenticated-orcid":false,"given":"Jeremy S.","family":"Nayagam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Parente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2626-4341","authenticated-orcid":false,"given":"Matthew","family":"Seager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Sadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-7980","authenticated-orcid":false,"given":"Aldo J.","family":"Montano-Loza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/hep.24247","article-title":"Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"53","author":"Molodecky","year":"2011","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101748_bib2","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/liv.15007","article-title":"Global incidence, prevalence and features of primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"41","author":"Mehta","year":"2021","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib3","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib4","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis","volume":"152","author":"Weismuller","year":"2017","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib5","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.cgh.2021.08.039","article-title":"Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies","volume":"20","author":"Trivedi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101748_bib6","series-title":"Annual report 2021","year":"2021"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib7","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"2018 annual report of the European liver transplant registry (ELTR) - 50-year evolution of liver transplantation","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib8","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1053\/j.gastro.2009.08.070","article-title":"Long-term probability of and mortality from de novo malignancy after liver transplantation","volume":"137","author":"Watt","year":"2009","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib9","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.dld.2024.01.175","article-title":"Trends in liver transplantation for primary sclerosing cholangitis","volume":"56","author":"Morelli","year":"2024","journal-title":"Dig Liver Dis"},{"issue":"9","key":"10.1016\/j.jhepr.2026.101748_bib10","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1097\/TXD.0000000000000548","article-title":"Indications and outcomes in liver transplantation in patients with primary sclerosing cholangitis in Norway","volume":"1","author":"Andersen","year":"2015","journal-title":"Transpl Direct"},{"key":"10.1016\/j.jhepr.2026.101748_bib11","article-title":"Liver transplantation for cholestatic liver diseases: timing and disease recurrence","author":"Cancado","year":"2025","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib12","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.dld.2025.02.001","article-title":"PSC-specific prognostic scores associated with graft loss and overall mortality in recurrent PSC after liver transplantation","volume":"57","author":"Lytvyak","year":"2025","journal-title":"Dig Liver Dis"},{"issue":"11","key":"10.1016\/j.jhepr.2026.101748_bib13","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/lt.22396","article-title":"Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era","volume":"17","author":"Goldberg","year":"2011","journal-title":"Liver Transpl"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000590","article-title":"Management of primary sclerosing cholangitis: current state-of-the-art","volume":"8","author":"Cancado","year":"2024","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm14062098","article-title":"Performance of the Mayo risk score in predicting transplant and mortality in a single-center U.S. Cohort of primary sclerosing cholangitis","volume":"14","author":"Kahan","year":"2025","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib16","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1053\/j.gastro.2021.07.046","article-title":"Defining primary sclerosing cholangitis: results from an international primary sclerosing cholangitis study group consensus process","volume":"161","author":"Ponsioen","year":"2021","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101748_bib17","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis","volume":"67","author":"de Vries","year":"2018","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib18","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","article-title":"Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis","volume":"71","author":"Goet","year":"2019","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib19","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101748_bib20","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/liv.13402","article-title":"Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study","volume":"37","author":"de Vries","year":"2017","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep.31069","article-title":"Machine learning in a complex disease: PREsTo improves the prognostication of primary sclerosing cholangitis","volume":"71","author":"Shung","year":"2020","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib22","article-title":"Development of a prognostic MRCP-score (DiStrict) for individuals with large-duct primary sclerosing cholangitis","volume":"4","author":"Grigoriadis","year":"2022","journal-title":"JHEP Rep"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib23","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.14309\/ajg.0000000000000461","article-title":"The complementary value of magnetic resonance imaging and vibration-controlled transient elastography for risk stratification in primary sclerosing cholangitis","volume":"114","author":"Cazzagon","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"13","key":"10.1016\/j.jhepr.2026.101748_bib24","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1016\/j.cgh.2019.03.013","article-title":"Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Lemoinne","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101748_bib25","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0168-8278(24)00431-8","article-title":"GS-007 Prospective validation of the prognostic value of liver stiffness assessed by Fibroscan in primary sclerosing cholangitis: final results of the FICUS study","volume":"80","author":"Chazouill\u00e8res","year":"2024","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib26","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary sclerosing cholangitis","volume":"375","author":"Lazaridis","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib27","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101748_bib28","unstructured":"PSC Support. Secondary PSC support. https:\/\/pscsupport.org.uk\/surveys\/insights-living-with-psc\/."},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib29","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2024.07.032","article-title":"EASL clinical practice guidelines on liver transplantation","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0168-8278(98)80316-4","article-title":"Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers","volume":"28","author":"Olsson","year":"1998","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/lt.23587","article-title":"Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis","volume":"19","author":"Goldberg","year":"2013","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101748_bib32","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/liv.15271","article-title":"Symptom patterns in the daily life of PSC patients","volume":"42","author":"van Munster","year":"2022","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000153","article-title":"Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: open-label pilot study","volume":"7","author":"Bowlus","year":"2023","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/flgastro-2021-102025","article-title":"Nasobiliary drainage: an effective treatment for pruritus in cholestatic liver disease","volume":"13","author":"Ahmed","year":"2022","journal-title":"Frontline Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/apt.13449","article-title":"The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study","volume":"43","author":"Hegade","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib36","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/liv.15286","article-title":"Impact on follow-up strategies in patients with primary sclerosing cholangitis","volume":"43","author":"Bergquist","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101748_bib37","article-title":"Incidence of hepatobiliary malignancies in primary sclerosing cholangitis: systematic review and meta-analysis","author":"Souza","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib38","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0168-8278(01)00288-4","article-title":"Hepatic and extrahepatic malignancies in primary sclerosing cholangitis","volume":"36","author":"Bergquist","year":"2002","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101748_bib39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/003655202760373434","article-title":"Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation","volume":"37","author":"Boberg","year":"2002","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1478-3231.2011.02575.x","article-title":"Malignancies and mortality in 200 patients with primary sclerosering cholangitis: a long-term single-centre study","volume":"32","author":"Fevery","year":"2012","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib41","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2022.11.011","article-title":"Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis","volume":"78","author":"Villard","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jhepr.2026.101748_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113157","article-title":"Selected patients with unresectable perihilar cholangiocarcinoma (pCCA) derive long-term benefit from liver transplantation","volume":"12","author":"Azad","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish","year":"2012","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051353","article-title":"Cholangiocarcinoma as an indication for liver transplantation in the era of transplant oncology","volume":"9","author":"Gringeri","year":"2020","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib45","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib46","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/hep.28744","article-title":"Liver transplantation for \"very early\" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"issue":"10139","key":"10.1016\/j.jhepr.2026.101748_bib47","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib48","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1002\/hep.26977","article-title":"Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis","volume":"59","author":"Boonstra","year":"2014","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib49","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.22441","article-title":"Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis","volume":"48","author":"Charatcharoenwitthaya","year":"2008","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib50","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12876-019-1075-0","article-title":"Association between serum IgG level and clinical course in primary sclerosing cholangitis","volume":"19","author":"Hippchen","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.diii.2013.12.001","article-title":"Anatomy of liver arteries for interventional radiology","volume":"96","author":"Favelier","year":"2015","journal-title":"Diagn Interv Imag"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib52","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/jgh3.12405","article-title":"The impact of primary sclerosing cholangitis or inflammatory bowel disease on cholangiocarcinoma phenotype, therapy, and survival","volume":"4","author":"Chahal","year":"2020","journal-title":"JGH Open"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib53","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib54","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib55","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41395-018-0265-7","article-title":"Non-invasive prediction of high-risk varices in patients with primary biliary cholangitis and primary sclerosing cholangitis","volume":"114","author":"Moctezuma-Velazquez","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib56","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101775","article-title":"Non-invasive diagnosis and follow-up of primary sclerosing cholangitis","volume":"46","author":"Chazouilleres","year":"2022","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101748_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2372257","article-title":"ERCP-related adverse events in primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"2022","author":"Natt","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib59","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.cgh.2023.04.004","article-title":"Recent advances in the management of primary sclerosing cholangitis","volume":"21","author":"Assis","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17474124.2025.2450723","article-title":"PSC patient with jaundice - should we ERCP?","volume":"19","author":"Tayyub","year":"2025","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib61","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.gie.2013.09.015","article-title":"Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"79","author":"Trikudanathan","year":"2014","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib62","first-page":"42","article-title":"Cholangioscopy and its role in primary sclerosing cholangitis","volume":"8","author":"Fung","year":"2020","journal-title":"Eur Med J Hepatol"},{"issue":"19","key":"10.1016\/j.jhepr.2026.101748_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194827","article-title":"Deep learning for automatic diagnosis and morphologic characterization of malignant biliary strictures using digital cholangioscopy: a multicentric study","volume":"15","author":"Saraiva","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jhepr.2026.101748_bib64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s11901-020-00514-0","article-title":"The role of cholangioscopy in the management of primary sclerosing cholangitis","volume":"19","author":"Montano-Loza","year":"2020","journal-title":"Curr Hepatol Rep"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib65","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1053\/j.gastro.2018.05.034","article-title":"No superiority of stents vs balloon dilatation for dominant strictures in patients with primary sclerosing cholangitis","volume":"155","author":"Ponsioen","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib66","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/hep4.1813","article-title":"Predictors of jaundice resolution and survival after endoscopic treatment of primary sclerosing cholangitis","volume":"6","author":"Eaton","year":"2022","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib67","doi-asserted-by":"crossref","first-page":"E769","DOI":"10.1055\/s-0043-123186","article-title":"EUS-FNA versus ERCP for tissue diagnosis of suspect malignant biliary strictures: a prospective comparative study","volume":"6","author":"Moura","year":"2018","journal-title":"Endosc Int Open"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib68","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2023.09.031","article-title":"Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two?","volume":"80","author":"van Munster","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib69","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1053\/j.gastro.2021.05.063","article-title":"AGA clinical practice update on endoscopic surveillance and management of colorectal dysplasia in inflammatory bowel diseases: expert review","volume":"161","author":"Murthy","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101748_bib70","article-title":"Liver transplantation is associated with a reduced risk of colorectal dysplasia in patients with IBD and concomitant PSC","author":"Coelho-Prabhu","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101748_bib71","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1093\/ibd\/izaa317","article-title":"Association of anti-TNF therapy with increased risk of acute cholangitis in patients with primary sclerosing cholangitis","volume":"27","author":"Kulkarni","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib72","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"10.1016\/j.jhepr.2026.101748_bib73","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1016\/j.cgh.2023.01.014","article-title":"Evaluation of tofacitinib in primary sclerosing cholangitis and associated colitis: a multicenter, retrospective study","volume":"21","author":"Schregel","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101748_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11729","article-title":"Liver transplantation for primary sclerosing cholangitis (PSC) with or without inflammatory bowel disease (IBD)-A European society of organ transplantation (ESOT) consensus statement","volume":"36","author":"Carbone","year":"2023","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib75","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1478-3231.2011.02677.x","article-title":"The impact of inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis","volume":"33","author":"Joshi","year":"2013","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib76","article-title":"Inflammatory conditions play a role in recurrence of PSC after liver transplantation: an international multicentre study","volume":"4","author":"Visseren","year":"2022","journal-title":"JHEP Rep"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib77","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/lt.21679","article-title":"A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts","volume":"15","author":"Alabraba","year":"2009","journal-title":"Liver Transpl"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib78","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.15148","article-title":"Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation","volume":"49","author":"Steenstraten","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib79","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/tri.13925","article-title":"Recurrence of primary sclerosing cholangitis after liver transplantation - analysing the European Liver Transplant Registry and beyond","volume":"34","author":"Visseren","year":"2021","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhepr.2026.101748_bib80","article-title":"Long-term outcomes following colectomy and liver transplantation for inflammatory bowel disease with primary sclerosing cholangitis","author":"Matar","year":"2024","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib81","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.13894","article-title":"Systematic review: recurrent autoimmune liver diseases after liver transplantation","volume":"45","author":"Montano-Loza","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib82","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1097\/SLA.0000000000006041","article-title":"Ileal pouch-anal anastomosis in primary sclerosing cholangitis-inflammatory bowel disease (PSC-IBD): long-term pouch and liver transplant outcomes","volume":"278","author":"Maspero","year":"2023","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib83","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/apt.14828","article-title":"The impact of ileal pouch-anal anastomosis on graft survival following liver transplantation for primary sclerosing cholangitis","volume":"48","author":"Trivedi","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib84","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/SLA.0b013e318204e658","article-title":"Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis","volume":"253","author":"Jay","year":"2011","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib85","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1097\/TP.0000000000000447","article-title":"Donation after cardiac death liver transplantation in primary sclerosing cholangitis: proceed with caution","volume":"99","author":"Sundaram","year":"2015","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib86","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14521","article-title":"Liver transplant after donation from controlled circulatory death versus brain death: a UNOS database analysis and publication bias adjusted meta-analysis","volume":"36","author":"Ziogas","year":"2022","journal-title":"Clin Transpl"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib87","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jhep.2017.06.027","article-title":"Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis","volume":"67","author":"Trivedi","year":"2017","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib88","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000219","article-title":"Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis","volume":"7","author":"Onofrio","year":"2023","journal-title":"Hepatol Commun"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib89","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/LVT.0000000000000374","article-title":"Pursuing living donor liver transplantation improves outcomes of patients with autoimmune liver diseases: an intention-to-treat analysis","volume":"30","author":"Jones","year":"2024","journal-title":"Liver Transpl"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib90","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082807","article-title":"Living-donor liver transplant and improved post-transplant survival in patients with primary sclerosing cholangitis","volume":"12","author":"Sierra","year":"2023","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib91","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12072-024-10733-y","article-title":"Impact of graft type on outcomes following liver transplantation for primary sclerosing cholangitis","volume":"19","author":"Kumar","year":"2025","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib92","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/ajt.16864","article-title":"Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: experience from the European Liver Transplant Registry","volume":"22","author":"Heinemann","year":"2022","journal-title":"Am J Transpl"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib93","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/j.1432-2277.2011.01371.x","article-title":"Duct-to-duct biliary reconstruction in orthotopic liver transplantation for primary sclerosing cholangitis: a viable and safe alternative","volume":"25","author":"Damrah","year":"2012","journal-title":"Transpl Int"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib94","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12964","article-title":"Biliary reconstruction in liver transplant patients with primary sclerosing cholangitis, duct-to-duct or Roux-en-Y?","volume":"31","author":"Shamsaeefar","year":"2017","journal-title":"Clin Transpl"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib95","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/tri.12513","article-title":"Meta-analysis of Duct-to-duct versus Roux-en-Y biliary reconstruction following liver transplantation for primary sclerosing cholangitis","volume":"28","author":"Pandanaboyana","year":"2015","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib96","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/lt.23827","article-title":"Duct-to-duct reconstruction in liver transplantation for primary sclerosing cholangitis is associated with fewer biliary complications in comparison with hepaticojejunostomy","volume":"20","author":"Sutton","year":"2014","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib97","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2024.06.035","article-title":"Long-term outcomes after hypothermic oxygenated machine perfusion and transplantation of 1,202 donor livers in a real-world setting (HOPE-REAL study)","volume":"82","author":"Eden","year":"2025","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib98","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jhep.2023.05.027","article-title":"Machine perfusion techniques for liver transplantation - a meta-analysis of the first seven randomized-controlled trials","volume":"79","author":"Parente","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib99","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2024.03.020","article-title":"Transplant benefit-based offering of deceased donor livers in the United Kingdom","volume":"81","author":"Allen","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101748_bib100","series-title":"Secondary ODT clinical - policies and guidance","year":"2025"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib101","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3138\/canlivj-2022-0026","article-title":"Exception points for liver transplantation: a Canadian review","volume":"6","author":"Congly","year":"2023","journal-title":"Can Liver J"},{"key":"10.1016\/j.jhepr.2026.101748_bib102","series-title":"Briefing to the OPTN Board of Directors on updating national liver review board guidance and policy clarification: Organ Procurement and Transplantation Network","year":"2021"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib103","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.gastro.2024.10.038","article-title":"AGA clinical practice update on management of portal vein thrombosis in patients with cirrhosis: expert review","volume":"168","author":"Davis","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.101748_bib104","series-title":"Wider, longer-term services needed for liver transplant patients. Secondary Wider, longer-term services needed for liver transplant patients","author":"Support","year":"2020"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib105","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s12072-007-9035-0","article-title":"Health-related quality of life and psychological correlates in patients listed for liver transplantation","volume":"1","author":"Gutteling","year":"2007","journal-title":"Hepatol Int"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib106","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jhep.2023.03.025","article-title":"Liver transplantation in the patient with physical frailty","volume":"78","author":"Tandon","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib107","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.29219","article-title":"Development of a novel frailty index to predict mortality in patients with end-stage liver disease","volume":"66","author":"Lai","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib108","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7861\/clinmed.2019-0257","article-title":"Prehabilitation","volume":"19","author":"Durrand","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jhepr.2026.101748_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2022.10330","article-title":"Physical effects, safety and feasibility of prehabilitation in patients awaiting orthotopic liver transplantation, a systematic review","volume":"35","author":"Jetten","year":"2022","journal-title":"Transpl Int"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib110","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3748\/wjg.v22.i4.1513","article-title":"Nutrition therapy: integral part of liver transplant care","volume":"22","author":"Anastacio","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib111","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cgh.2011.08.016","article-title":"Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies","volume":"10","author":"Cheung","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101748_bib112","first-page":"1","article-title":"Nutritional therapy to cirrhotic patients on transplantation waiting lists","volume":"5","author":"Ramachandran","year":"2022","journal-title":"J Liver Trans"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib113","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib114","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.02.013","article-title":"European association for the study of the L. Role of endoscopy in primary sclerosing cholangitis: European society of gastrointestinal endoscopy (ESGE) and European association for the study of the liver (EASL) clinical guideline","volume":"66","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib115","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib116","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/liv.14871","article-title":"Safety of fibrates in cholestatic liver diseases","volume":"41","author":"Carrion","year":"2021","journal-title":"Liver Int"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib117","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/apt.14579","article-title":"Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study","volume":"47","author":"Webb","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"8638","key":"10.1016\/j.jhepr.2026.101748_bib118","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(89)91608-5","article-title":"Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis","volume":"1","author":"Bachs","year":"1989","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib119","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American association for the study of liver diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib120","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1365-2125.2011.04158.x","article-title":"Severe coagulopathy caused by rifampicin in patients with primary sclerosing cholangitis and refractory pruritus","volume":"73","author":"Sampaziotis","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib121","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101748_bib122","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1007\/s10620-023-07862-z","article-title":"Cholestatic pruritus treatments in primary biliary cholangitis and primary sclerosing cholangitis: a systematic literature review","volume":"68","author":"Smith","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101748_bib123","article-title":"Safety of naltrexone in patients with cirrhosis","volume":"6","author":"Thompson","year":"2024","journal-title":"JHEP Rep"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib124","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study","volume":"37","author":"Terg","year":"2002","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib125","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/gast.1997.v113.pm9322521","article-title":"Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study","volume":"113","author":"Wolfhagen","year":"1997","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib126","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/hep.32378","article-title":"AASLD Practice Guidance: palliative care and symptom-based management in decompensated cirrhosis","volume":"76","author":"Rogal","year":"2022","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib127","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40262-014-0187-5","article-title":"Pharmacokinetics of antidepressants in patients with hepatic impairment","volume":"53","author":"Mauri","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib128","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.4088\/JCP.09r05786blu","article-title":"Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms","volume":"71","author":"Andrade","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1053\/jhep.2002.36088","article-title":"Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited","volume":"36","author":"Paumgartner","year":"2002","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib130","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0168-8278(98)80059-7","article-title":"Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses","volume":"29","author":"van Hoogstraten","year":"1998","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jhepr.2026.101748_bib131","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1872-034X.2009.00527.x","article-title":"Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials","volume":"39","author":"Shi","year":"2009","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib132","first-page":"CD003626","article-title":"Bile acids for primary sclerosing cholangitis","volume":"2011","author":"Poropat","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib133","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1365-2036.2011.04822.x","article-title":"Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis","volume":"34","author":"Triantos","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.jhepr.2026.101748_bib134","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.jhepr.2026.101748_bib135","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1007\/s00535-022-01914-3","article-title":"Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis","volume":"57","author":"Arizumi","year":"2022","journal-title":"J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib136","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jhepr.2026.101748_bib137","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101748_bib138","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000003659","article-title":"Recurrence of primary sclerosing cholangitis after liver transplantation: a French national cohort study including 571 patients","author":"Veyre","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib139","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/hep.510300501","article-title":"Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis","volume":"30","author":"Graziadei","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101748_bib140","article-title":"Recurrence of autoimmune liver diseases after liver transplantation: review and expert opinion statement","author":"Montano-Loza","year":"2024","journal-title":"Liver Transpl"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib141","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/lt.21394","article-title":"Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation","volume":"14","author":"Alexander","year":"2008","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib142","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1155\/2010\/830291","article-title":"The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation--a single-centre experience","volume":"24","author":"Moncrief","year":"2010","journal-title":"Can J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib143","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/PAS.0b013e3181c6c09a","article-title":"IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis","volume":"34","author":"Zhang","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.jhepr.2026.101748_bib144","doi-asserted-by":"crossref","first-page":"459","DOI":"10.14309\/ajg.0000000000002977","article-title":"Severe cholestasis predicts recurrent primary sclerosing cholangitis following liver transplantation","volume":"120","author":"Aziz","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib145","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: immunosuppression, rejection, and immunomodulation","volume":"78","author":"Montano-Loza","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib146","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1034\/j.1600-6143.2003.00110.x","article-title":"De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant","volume":"3","author":"Heneghan","year":"2003","journal-title":"Am J Transpl"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101748_bib147","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1111\/j.1432-2277.2011.01324.x","article-title":"Cholangiocarcinoma complicating recurrent primary sclerosing cholangitis after liver transplantation","volume":"24","author":"Khorsandi","year":"2011","journal-title":"Transpl Int"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101748_bib148","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70002","article-title":"Recurrence of primary sclerosing cholangitis and de novo cholangiocarcinoma after liver transplantation: results from the Brazilian cholestasis consortium","volume":"38","author":"Bittencourt","year":"2024","journal-title":"Clin Transpl"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib149","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16214","article-title":"Outcome of liver retransplantation in patients with primary sclerosing cholangitis","volume":"45","author":"Molinaro","year":"2025","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib150","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jhep.2023.08.031","article-title":"Cyclosporine vs. tacrolimus after liver transplantation for primary sclerosing cholangitis - a propensity score-matched intention-to-treat analysis","volume":"80","author":"Aberg","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhepr.2026.101748_bib151","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/00365521.2017.1421705","article-title":"Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study","volume":"53","author":"Lindstrom","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhepr.2026.101748_bib152","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/lt.24350","article-title":"Biliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis: a retrospective multicenter analysis","volume":"22","author":"Hildebrand","year":"2016","journal-title":"Liver Transpl"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101748_bib153","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000693","article-title":"Outcomes of liver transplant recipients with autoimmune liver disease using long-term dual immunosuppression regimen without corticosteroid","volume":"3","author":"Satapathy","year":"2017","journal-title":"Transpl Direct"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib154","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/ibd\/izac132","article-title":"Alterations in the course of inflammatory bowel disease following liver transplantation: a systematic review and meta-analysis","volume":"29","author":"Safarpour","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib155","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/gut.43.5.639","article-title":"Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis","volume":"43","author":"Papatheodoridis","year":"1998","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.jhepr.2026.101748_bib156","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.cgh.2020.02.014","article-title":"Effects of tumor necrosis factor antagonists in patients with primary sclerosing cholangitis","volume":"18","author":"Hedin","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib157","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/phar.2036","article-title":"Safety and efficacy of biologic agents for the management of inflammatory bowel disease after liver transplantation","volume":"37","author":"Shaikh","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.jhepr.2026.101748_bib158","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1093\/ibd\/izad108","article-title":"Safety of biologic and small molecule therapy for inflammatory bowel disease among solid organ transplant recipients: systematic review and meta-analysis","volume":"30","author":"Taneja","year":"2024","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib159","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.semarthrit.2021.08.013","article-title":"Safety of biologic treatments in solid organ transplant recipients: a systematic review","volume":"51","author":"Meyer","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib160","first-page":"949","article-title":"Safety of combination biologic and antirejection therapy post-liver transplantation in patients with inflammatory bowel disease","volume":"26","author":"Al","year":"2020","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101748_bib161","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.dld.2018.02.014","article-title":"Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: a nationwide case series","volume":"50","author":"Altwegg","year":"2018","journal-title":"Dig Liver Dis"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib162","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/ibd\/izx096","article-title":"Natural history of established and de novo inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis","volume":"24","author":"Mouchli","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.jhepr.2026.101748_bib163","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/j.1600-6143.2006.01333.x","article-title":"Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease","volume":"6","author":"Verdonk","year":"2006","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1016\/j.jhepr.2026.101748_bib164","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cgh.2012.12.027","article-title":"Immunosuppression after liver transplantation for primary sclerosing cholangitis influences activity of inflammatory bowel disease","volume":"11","author":"Jorgensen","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib165","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1097\/00042737-200512000-00018","article-title":"The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation","volume":"17","author":"Ho","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.jhepr.2026.101748_bib166","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/MIB.0000000000001105","article-title":"Clinical course of ulcerative colitis after liver transplantation in patients with concomitant primary sclerosing cholangitis and ulcerative colitis","volume":"23","author":"Fattahi","year":"2017","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.jhepr.2026.101748_bib167","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/TP.0000000000001725","article-title":"Risk factors and outcomes of de novo cancers (excluding nonmelanoma skin cancer) after liver transplantation for primary sclerosing cholangitis","volume":"101","author":"Mouchli","year":"2017","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.jhepr.2026.101748_bib168","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/lt.23741","article-title":"Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis","volume":"19","author":"Singh","year":"2013","journal-title":"Liver Transpl"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926000182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T11:37:18Z","timestamp":1775475438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926000182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":168,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2589555926000182"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101748","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and management of primary sclerosing cholangitis patients awaiting liver transplantation","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101748"}}